On May 29, 2024 Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop a functional cure for people with chronic hepatitis B virus (cHBV) infection, reported that the Arbutus management team will present at and host one-on-one meetings at the following upcoming investor conference being held in New York (Press release, Arbutus Biopharma, MAY 29, 2024, View Source [SID1234643774]):

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Jefferies Global Healthcare Conference: Formal Presentation on June 5, 2024 at 9:30 am ET

To access the live webcast of the presentation, please visit: View Source An archived replay of the webcast will be available on the Arbutus website for a limited time after the event.